Christopher Michael Lyons Purchases 7,534 Shares of Sintx Technologies (NASDAQ:SINT) Stock

Sintx Technologies, Inc. (NASDAQ:SINT) Director Christopher Michael Lyons purchased 7,534 shares of the business’s stock in a transaction dated Monday, March 2nd. The stock was bought at an average cost of $2.90 per share, with a total value of $21,848.60. Following the completion of the acquisition, the director directly owned 8,292 shares of the company’s stock, valued at approximately $24,046.80. This trade represents a 993.93% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link.

Christopher Michael Lyons also recently made the following trade(s):

• On Wednesday, February 25th, Christopher Michael Lyons purchased 758 shares of Sintx Technologies stock. The stock was bought at an average price of $2.96 per share, with a total value of $2,243.68.

Sintx Technologies Stock Up 0.8%

SINT traded up $0.02 during trading on Tuesday, reaching $2.77. 20,589 shares of the company were exchanged, compared to its average volume of 34,135. The company’s 50-day moving average is $3.28 and its two-hundred day moving average is $3.67. The company has a market cap of $10.20 million, a price-to-earnings ratio of -0.49 and a beta of 0.66. Sintx Technologies, Inc. has a 12-month low of $1.71 and a 12-month high of $6.78.

Institutional Trading of Sintx Technologies

Hedge funds have recently made changes to their positions in the stock. Virtus Wealth Solutions LLC purchased a new position in Sintx Technologies in the third quarter worth $388,000. Veracity Capital LLC raised its position in Sintx Technologies by 10.3% during the third quarter. Veracity Capital LLC now owns 79,928 shares of the company’s stock valued at $327,000 after purchasing an additional 7,464 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in Sintx Technologies by 53.4% during the fourth quarter. Geode Capital Management LLC now owns 26,624 shares of the company’s stock worth $103,000 after purchasing an additional 9,265 shares during the last quarter. 18.38% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on SINT. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sintx Technologies in a report on Thursday, January 22nd. Ascendiant Capital Markets cut their price target on shares of Sintx Technologies from $25.00 to $16.00 and set a “buy” rating for the company in a report on Monday, December 8th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $16.00.

About Sintx Technologies

Sintx Technologies, Inc (NASDAQ: SINT) is a medical materials company specializing in the development and manufacture of silicon nitride-based biomaterials for surgical and implantable medical devices. Its proprietary silicon nitride ceramic combines mechanical strength, biocompatibility and intrinsic antimicrobial properties, positioning it as an alternative to traditional metal and polymer implant materials. Sintx’s primary focus is on applications in spinal fusion, trauma fixation and dental implantology, where device performance and long-term biological response are critical.

The company’s core product offerings include silicon nitride powders for advanced implant fabrication and finished implantable components designed for interbody spinal fusion cages, spinal fixation hardware and trauma plates and screws.